271 Cerebellar Metastasis of Prostatic Ductal Adenocarcinoma, Beyond What We Know

Molecular approaches to diagnosis of invasive aspergillosis what we know and what we do not know.

Invasive aspergillosis (IA) are a major complication in immunocompromized patients where can be serious and rapidly fatal. Early diagnosis and early appropriate antifungal treatment is important in reducing mortality and morbidity. But despite many efforts to develop detection methods, the diagnosis of IA still remains challenging and current conventional methods are limited for adequate diagno...

Superior Capsule Reconstruction: What Do We Know?

The management of irreparable rotator cuff tears remains challenging. Since its introduction by Mihata in 2012, superiorcapsule reconstruction (SCR) has grown in popularity at an astonishingly rapid rate. The aim of this article is to providea comprehensive review of the available literature, in order to highlight what has so far been published on SCR,covering all aspects including biomechanica...

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma

Ductal adenocarcinoma (DCP) a variant of acinar adecocarcinoma (ACP), mainly occurs in patients aged 60-70 years. It is a very rare disease accounting for approximately 0.1 to 1% of all prostate cancers. Although its progress is more aggressive than the acinar type, guidelines for its treatment and follow-up have not been confirmed yet. According to Meekset al., the prevalence of ductal typepro...

Prostatic Ductal Adenocarcinoma

Han Jung, Han Sae Lee, Sang Jin Yoon, Khae Hawn Kim From the Department of Urology, Gachon University Gil Hospital, Incheon, Korea Prostatic ductal adenocarcinoma is a rare neoplasm that develops from the prostatic urethra. We present an 85-year-old man with an exophytic lesion in the prostatic cavity, which was diagnosed after transurethral resection of the prostate. Histopathologically, the t...

Do We Know What We Do not Know? A Response to Celine Bonnet